ACRS — Aclaris Therapeutics, Inc.
Is ACRS overbought or oversold? Here is the current MarketMoodz read.
Aclaris Therapeutics, Inc. (ACRS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.61. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$3.61
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Aclaris Therapeutics, Inc. sits as a small-cap specialty biotech with potential upside tied to pipeline and regulatory catalysts, but it is exposed to typical sector volatility and funding/dilution sensitivity. Market conditions currently favor large-cap pharma and defensive healthcare flows, which may limit near-term investor appetite. The absence of recent filing details in the provided dataset increases uncertainty about near-term financial runway and capital plans. Positive clinical or commercial developments would materially improve the outlook, while financing needs, competitive pressure from larger players, or adverse trial/regulatory outcomes would present the primary downside scenarios.
Key factors
- Niche dermatology / specialty-biotech focus with potential pipeline catalysts that can re-rate the stock if clinical readouts or regulatory progress are positive
- Small-cap profile means share price is sensitive to sentiment, financing needs, and discrete news events rather than broad market moves
- Current market backdrop favors large-cap pharma and defensive healthcare flows, which can limit investor interest in smaller biotech names
- Limited publicly available recent EDGAR/filing detail in the provided dataset increases uncertainty around near-term financial runway and capital structure
- Readthroughs from sector themes (e.g., distributor shift to specialty care) could benefit commercial channels if pipeline products reach market
Risks
- Financing and dilution risk if cash runway is constrained; mid-cap/small-cap biotech often access equity or convertible financing under pressure
- Clinical and regulatory risk: negative trial results or delayed approvals would materially impact valuation
- Commercial execution risk: competing larger pharma entrants and established therapies could limit uptake of any approved products
- Market-flow risk: rotation into large-cap pharma/defensive ETFs may reduce liquidity and suppress multiple expansion for small-biotech names
- Operational risk from limited available public financial detail in the short-term (no EDGAR comparison provided), increasing uncertainty for investors
See today's live rating, score and targets
Members see the live hourly rating for ACRS — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.